Cell therapy for the preterm infant: promise and practicalities.

Area of Science:

• Neonatal Medicine
• Regenerative Medicine
• Developmental Neuroscience

Background:

• Neonatal intensive care advances improve survival rates for extremely preterm infants.
• Improved survival reveals new morbidities like bronchopulmonary dysplasia and preterm brain injury.
• Inflammation, immaturity, and progenitor cell exhaustion contribute to these injuries.

Purpose of the Study:

• To review the rationale for using cell therapy in extremely preterm infants.
• To examine preclinical and early clinical evidence for cell therapy in bronchopulmonary dysplasia and preterm brain injury.
• To discuss challenges in translating cell therapy to clinical practice.

Main Methods:

• Literature review of preclinical studies.
• Analysis of early-phase clinical trial data.
• Discussion of translational challenges.

Main Results:

• Cell therapy, utilizing stem and stem-like cells, shows potential for injury repair and prevention.
• Preclinical and early clinical data support cell therapy for bronchopulmonary dysplasia and preterm brain injury.
• Existing therapies do not fully address novel injury mechanisms like cell exhaustion.

Conclusions:

• Cell therapy presents a novel therapeutic strategy for extremely preterm infants.
• Further research and clinical trials are needed to overcome translational hurdles.
• Addressing progenitor cell exhaustion is crucial for improving long-term outcomes.